ASH 2018 News - Episode 2

OncLive News Network On Location: In San Diego Sunday, December 2


We are on site at the San Diego Convention Center in California at the 2018 ASH Annual Meeting!

We’ll be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Dr Ruben Mesa on the myeloproliferative neoplasm data, Dr Pinkal Desai on the top acute myeloid leukemia abstracts, and C. Ola Landgren on the pivotal multiple myeloma studies.

Welcome to OncLive News Network! I’m Gina Columbus.

Results of the phase III TRANSCEND 004 study showed that the chimeric antigen receptor T-cell therapy lisocabtagene maraleucel had manageable toxicity and encouraging clinical activity in heavily pretreated patients with chronic lymphocytic leukemia.

Complete responses and undetectable minimal residual disease were achieved with liso-cel in both patients with high-risk and standard-risk disease who previously received ibrutinib and the majority of whom were treated with venetoclax.


In acute myeloid leukemia, venetoclax combined with either azacitidine or decitabine led to high rates of rapid, deep, and durable responses in patient’s ineligible for standard induction chemotherapy.

Additionally, the combination of venetoclax with low-dose cytarabine was also linked with encouraging responses in patients with AML who were ineligible for intensive chemotherapy.


In multiple myeloma, the chimeric antigen receptor T-cell therapy bb21217 showed early signs of efficacy in relapsed/refractory patients. Moreover, the safety profile was consistent with known toxicities of CAR T therapies.

Longer follow-up and a larger number of patients will confirm whether bb21217 leads to sustained CAR T-cell persistence and responses.


Findings from the randomized phase III AUGMENT trial showed that the combination of lenalidomide and rituximab improved progression-free survival versus rituximab plus placebo in previously treated patients with relapsed/refractory grade 1 to 3a follicular lymphoma and marginal zone lymphoma.

Overall response rate, complete response, duration of response, and time-to-next anti-lymphoma treatment were also met with R2. Fewer deaths also occurred with the combination.


In multiple myeloma, findings of the phase III TOURMALINE-MM1 trial showed that weekly maintenance treatment with ixazomib demonstrated a reduction in the risk of progression or death in patients with newly diagnosed patients who had at least a partial response to induction therapy with a proteasome inhibitor and/or immunomodulatory drug followed by single ASCT.

Ixazomib led to deep responses, increased conversions to minimal residual negativity over control, and a manageable safety profile. Patients on the maintenance treatment had an absence of risk of second primary malignancies and low rates of peripheral neuropathy.


That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location, where we will sit down with Dr Brad Kahl of Washington University School of Medicine in St. Louis to highlight the recent findings in non-Hodgkin lymphoma, Dr William Wierda of the University of Texas MD Anderson Cancer to share insight on chronic lymphocytic leukemia abstracts, and Owen O‘Connor of Columbia University Medical Center on some of the mantle cell lymphoma and T-cell lymphoma trials.

Thank you for watching OncLive News Network! I’m Gina Columbus.